keyword
MENU ▼
Read by QxMD icon Read
search

Rifaximin

keyword
https://www.readbyqxmd.com/read/28814581/hyperammonaemic-encephalopathy-following-an-uncomplicated-surgery
#1
Stuart McIntosh, Karima Medjoub, Kevin Deans, Sara Sexton
A 59-year-old woman who underwent an uncomplicated exploratory laparotomy, adhesiolysis, small bowel resection and anterolateral thigh flap had a complicated postoperative period characterised by wound dehiscence and poor nutritional intake. 29 days postoperatively, a tremor developed in her upper limbs associated with weakness. Her Glasgow Coma Scale (GCS) fell to 4 and she was transferred to the intensive care unit. The patient was reviewed by multiple specialists and multiple differentials were considered and eliminated...
August 16, 2017: BMJ Case Reports
https://www.readbyqxmd.com/read/28799305/comparison-of-rifaximin-plus-lactulose-with-the-lactulose-alone-for-the-treatment-of-hepatic-encephalopathy
#2
Kiran Ahire, Archana Sonawale
INTRODUCTION: Hepatic encephalopathy is challenging complication of liver dysfunction. Therapeutic treatment options for hepatic encephalopathy are currently limited and have appreciable risks and benefits associated with their use. Rifaximin is a novel anti microbiological agent with wide spectrum of activity that has shown promise as an alternative option for hepatic encephalopathy. AIMS AND OBJECTIVE: The present study was undertaken to compare the effectiveness of Rifaximin and Lactulose as a combination vs Lactulose alone, to compare the adverse effects and to study the rapidity of therapeutic effects of Rifaximin and Lactulose...
August 2017: Journal of the Association of Physicians of India
https://www.readbyqxmd.com/read/28780968/efficacy-and-safety-of-rifaximin-associated-with-standard-triple-therapy-omeprazole-clarithromycin-and-amoxicillin-for-h-pylori-eradication-a-phase-iv-pilot-clinical-trial
#3
Mercedes Ramas, Maria G Donday, Adrian G McNicholl, Javier P Gisbert
BACKGROUND: A progressive decrease in Helicobacter pylori eradication rates has been described over the years, driving the need for new antibiotic treatments. AIM: To evaluate the efficacy and safety of the addition of rifaximin (Spiraxin(®)) to standard triple therapy (omeprazole, amoxicillin and clarithromycin) for the eradication of H. pylori. METHODS: Independent prospective clinical trial (EUDRACT no.: 2013-001080-23). Forty consecutive adult patients were included with H...
August 3, 2017: Gastroenterología y Hepatología
https://www.readbyqxmd.com/read/28763340/rifaximin-for-the-prevention-of-spontaneous-bacterial-peritonitis-and-hepatorenal-syndrome-in-cirrhosis-a-systematic-review-and-meta-analysis
#4
Faisal Kamal, Muhammad Ali Khan, Zubair Khan, George Cholankeril, Tariq A Hammad, Wade M Lee, Aijaz Ahmed, Bradford Waters, Colin W Howden, Satheesh Nair, Sanjaya K Satapathy
Prophylactic antibiotics have been recommended in patients with a previous history of spontaneous bacterial peritonitis (SBP). Recently, there has been interest in the use of rifaximin for the prevention of SBP and hepatorenal syndrome (HRS). We conducted a meta-analysis to evaluate this association of rifaximin. We searched several databases from inception through 24 January 2017, to identify comparative studies evaluating the effect of rifaximin on the occurrence of SBP and HRS. We performed predetermined subgroup analyses based on the type of control group, design of the study, and type of prophylaxis...
July 31, 2017: European Journal of Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/28762323/rifaximin-stability-a-look-at-uv-ir-hplc-and-turbidimetry-methods
#5
Ana Carolina Kogawa, Hérida Regina Nunes Salgado
The study of the stability of medicines is mandated by the International Conference on Harmonization and the World Health Organization. Rifaximin, an antimicrobial marketed in the form of tablets, has no record of stability studies. Thus, the objective of the present work was to investigate the behavior and stability of rifaximin tablets for 6 months under simultaneous conditions of temperature and humidity by UV, IR, HPLC, and turbidimetry techniques. After 6 months of stability study, rifaximin tablets were shown to obey zero-order kinetics when analyzed by physicochemical methods and second-order kinetics when analyzed by a microbiological method...
July 31, 2017: Journal of AOAC International
https://www.readbyqxmd.com/read/28740337/eubiotic-properties-of-rifaximin-disruption-of-the-traditional-concepts-in-gut-microbiota-modulation
#6
REVIEW
Francesca Romana Ponziani, Maria Assunta Zocco, Francesca D'Aversa, Maurizio Pompili, Antonio Gasbarrini
Antibiotics are usually prescribed to cure infections but they also have significant modulatory effects on the gut microbiota. Several alterations of the intestinal bacterial community have been reported during antibiotic treatment, including the reduction of beneficial bacteria as well as of microbial alpha-diversity. Although after the discontinuation of antibiotic therapies it has been observed a trend towards the restoration of the original condition, the new steady state is different from the previous one, as if antibiotics induced some kind of irreversible perturbation of the gut microbial community...
July 7, 2017: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/28729815/symposium-report-an-evidence-based-approach-to-ibs-and-cic-applying-new-advances-to-daily-practice-a-review-of-an-adjunct-clinical-symposium-of-the-american-college-of-gastroenterology-meeting-october-16-2016-%C3%A2-las-vegas-nevada
#7
William D Chey
Many nonpharmacologic and pharmacologic therapies are available to manage irritable bowel syndrome (IBS) and chronic idiopathic constipation (CIC). The American College of Gastroenterology (ACG) regularly publishes reviews on IBS and CIC therapies. The most recent of these reviews was published by the ACG Task Force on the Management of Functional Bowel Disorders in 2014. The key objective of this review was to evaluate the efficacy of therapies for IBS or CIC compared with placebo or no treatment in randomized controlled trials...
February 2017: Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/28702105/the-effect-of-cyclic-rifaximin-therapy-on-symptoms-of-diverticular-disease-from-the-perspective-of-the-gastroenterology-outpatient-clinic-a-real-life-study
#8
Andrzej Moniuszko, Grażyna Rydzewska
INTRODUCTION: Symptomatic uncomplicated diverticular disease of the colon (SUDD) is one of the most common diseases with which patients present to a gastroenterologist. Mild forms of diverticulitis can also be treated using rifaximin. Although numerous randomised controlled trials have already demonstrated the efficacy of rifaximin therapy, there is still a lack of data from daily medical practice. AIM: To assess the effect of rifaximin on the symptoms of diverticular disease (SUDD and mild diverticulitis) in patients undergoing routine treatment in gastroenterology outpatient clinics in Poland...
2017: Przegla̜d Gastroenterologiczny
https://www.readbyqxmd.com/read/28697313/rifamycin-sv-mmx-for-the-treatment-of-traveler-s-diarrhea
#9
Shu-Wen Lin, Chun-Jung Lin, Jyh-Chin Yang
Rifamycin SV MMX®, a non-absorbable rifamycin antibiotic formulated using the multi-matrix system, was designed to exhibit its pharmacological action on the distal small intestine and colon. Its clinical efficacy and safety profile in the treatment of traveler's diarrhea were evaluated in several clinical studies. Areas covered: This review summarizes all available evidence regarding clinical trials of the efficacy and safety profile of rifamycin SV MMX for the treatment of traveler's diarrhea. Expert opinion: Rifamycin SV MMX demonstrated an excellent pharmacokinetic profile with decreased systemic toxicity similar to rifaximin...
July 27, 2017: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/28671712/rifaximin-has-minor-effects-on-bacterial-composition-inflammation-and-bacterial-translocation-in-cirrhosis-a-randomized-trial
#10
Nina Kimer, Julie S Pedersen, Juliette Tavenier, Jeffrey E Christensen, Troels M Busk, Lise Hobolth, Aleksander Krag, Waleed Abu Al-Soud, Martin S Mortensen, Søren J Sørensen, Søren Møller, Flemming Bendtsen
BACKGROUND & AIMS: Decompensated cirrhosis is characterized by disturbed haemodynamics, immune dysfunction, and high risk of infections. Translocation of viable bacteria and bacterial products from the gut to the blood is considered a key driver in this process. Intestinal decontamination with rifaximin may reduce bacterial translocation (BT) and decrease inflammation. In a randomized, placebo-controlled trial investigated the effects of rifaximin on inflammation and BT in decompensated cirrhosis...
July 3, 2017: Journal of Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/28666309/rediscover-the-clinical-value-of-small-intestinal-bacterial-overgrowth-in-patients-with-intestinal-beh%C3%A3-et-s-disease
#11
Jung Hyun Jo, Soo Jung Park, Jae Hee Cheon, Tae Il Kim, Won Ho Kim
Background/Aims Many patients with intestinal Behçet's disease (BD) still suffer from gastrointestinal symptoms despite the disease being in endoscopic or radiological remission. Previous studies report that small intestinal bacterial overgrowth (SIBO) can be associated with inflammatory bowel disease. However, there have been no reports about SIBO in patients with intestinal BD. We sought to identify the frequency of SIBO in patients with inactive intestinal BD by HBT and to investigate the efficacy of rifaximin as a treatment for SIBO...
June 30, 2017: Journal of Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/28651304/rifaximin-and-propranolol-combination-therapy-is-more-effective-than-propranolol-monotherapy-for-the-reduction-of-portal-pressure-an-open-randomized-controlled-pilot-study
#12
Yoo Li Lim, Moon Young Kim, Yoon Ok Jang, Soon Koo Baik, Sang Ok Kwon
Background/Aims: Non-selective beta blockers (NSBBs) are currently the only accepted regimen for preventing portal hypertension (PHT)-related complications. However, the effect of NSBBs is insufficient in many cases. Bacterial translocation (BT) is one of the aggravating factors of PHT in cirrhosis; therefore, selective intestinal decontamination by rifaximin is a possible therapeutic option for improving PHT. We investigated whether the addition of rifaximin to propranolol therapy can improve hepatic venous pressure gradient (HVPG) response...
June 27, 2017: Gut and Liver
https://www.readbyqxmd.com/read/28646286/rifaximin-re-treatment-in-patients-with-irritable-bowel-syndrome-feels-like-the-first-time
#13
EDITORIAL
Francesca Romana Ponziani, Maurizio Pompili, Antonio Gasbarrini
No abstract text is available yet for this article.
June 23, 2017: Digestive Diseases and Sciences
https://www.readbyqxmd.com/read/28626122/pharmacological-properties-and-clinical-findings-of-rifaximin-rifxima-%C3%A2-tablets-200%C3%A2-mg
#14
Satoru Tamaoki, Ikuya Sato
No abstract text is available yet for this article.
2017: Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica
https://www.readbyqxmd.com/read/28622735/rifampin-resistant-staphylococcus-aureus-bacteremia-in-a-patient-on-chronic-rifaximin
#15
Paul O Lewis, Imran Khan, Paras Patel
No abstract text is available yet for this article.
July 2017: Annals of Pharmacotherapy
https://www.readbyqxmd.com/read/28608124/-diverticulitis-domain-of-conservative-or-drug-therapy
#16
REVIEW
S Böhm, W Kruis
Increasing interest in diverticular disease by the scientific community in the last 10-15 years has resulted in an increased number of publications. Among other things, nonevidence-based therapeutic paradigms were tested in randomized, controlled therapy studies. The importance of surgery in the therapy of diverticulitis has diminished in recent years; in particular, it has no role in the treatment of diverticulitis types 1a, 1b, and 2a according to the Classification of Diverticular Disease (CDD) treated successfully by conservative means...
June 12, 2017: Der Internist
https://www.readbyqxmd.com/read/28603609/antimicrobial-susceptibility-of-clostridium-difficile-isolated-in-thailand
#17
Papanin Putsathit, Monthira Maneerattanaporn, Pipat Piewngam, Daniel R Knight, Pattarachai Kiratisin, Thomas V Riley
BACKGROUND: Exposure to antimicrobials is the major risk factor associated with Clostridium difficile infection (CDI). Paradoxically, treatment of CDI with antimicrobials remains the preferred option. To date, only three studies have investigated the antimicrobial susceptibility of C. difficile from Thailand, two of which were published in the 1990s. This study aimed to investigate the contemporary antibiotic susceptibility of C. difficile isolated from patients in Thailand. METHODS: A collection of 105 C...
2017: Antimicrobial Resistance and Infection Control
https://www.readbyqxmd.com/read/28589238/repeat-rifaximin-for-irritable-bowel-syndrome-no-clinically-significant-changes-in-stool-microbial-antibiotic-sensitivity
#18
M Pimentel, B D Cash, A Lembo, R A Wolf, R J Israel, P Schoenfeld
BACKGROUND: Rifaximin has demonstrated efficacy and safety for diarrhea-predominant irritable bowel syndrome (IBS-D). AIM: To determine the rifaximin repeat treatment effect on fecal bacterial antibiotic susceptibility. METHODS: Patients with IBS in Trial 3 (TARGET 3) study who responded to open-label rifaximin 550 mg three times daily for 2 weeks, with symptom recurrence within 18 weeks, were randomized to double-blind treatment: two 2-week repeat courses of rifaximin or placebo, separated by 10 weeks...
June 6, 2017: Digestive Diseases and Sciences
https://www.readbyqxmd.com/read/28573746/rifaximin-exerts-beneficial-effects-in-pi-ibs-mouse-model-beyond-gut-microbiota
#19
Yu Jin, Xiaoyang Ren, Gangping Li, Ying Li, Lei Zhang, Huan Wang, Wei Qian, Xiaohua Hou
BACKGROUND AND AIMS: Rifaximin is a minimally absorbed antibiotic which has shown efficacy in irritable bowel syndrome (IBS) patients. However, the mechanism how it effects in IBS is still incompletely defined. In this study, we used Trichinella spiralis infected PI-IBS mouse model, to assess the action of rifaximin on visceral hypersensitivity, barrier function, gut inflammation and microbiota. METHODS: PI-IBS model was established by Trichinella spiralis infection in mice...
June 1, 2017: Journal of Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/28548239/impact-of-barium-enema-on-acute-diverticulitis-recurrence-a-retrospective-cohort-study-of-349-patients
#20
Francisco J Medina-Fernández, Lidia Rodríguez-Ortiz, Dimas J Garcilazo-Arismendi, Elena Navarro-Rodríguez, Eva M Torres-Tordera, César A Díaz-López, Javier Briceño
AIM: Acute diverticulitis is becoming a health concern in western countries as its incidence is increasing. Currently, one of the accepted theories on possible causes of diverticular perforation is the impactation of faecal residuals into some diverticula. Our aim was to evaluate whether barium impactation might have a negative effect by promoting diverticular inflammation/rupture and thereby acute diverticulitis recurrence. METHODS: A retrospective cohort study (January 2005/December 2015) was conducted at the Reina Sofia University Hospital of Cordoba (Spain)...
May 26, 2017: Journal of Digestive Diseases
keyword
keyword
17795
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"